FDA and VA Plan Joint AIDS Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ROCKVILLE, Maryland-Researchers at the Food and Drug Administration and the Veteran’s Administrations will join in an effort to determine whether HIV infection or certain drugs used to treat it cause avascular necrosis (AVN). The disorder,

ROCKVILLE, Maryland—Researchers at the Food and Drug Administration and the Veteran’s Administrations will join in an effort to determine whether HIV infection or certain drugs used to treat it cause avascular necrosis (AVN). The disorder, the destruction of bone cells due to a deficient blood supply, commonly affects people with AIDS. The epidemiologic study will focus on suspected AVN cases registered with the Veterans Health Administration’s centralized HIV Registry, which contains data on approximately 50,000 patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.